Results 41 to 50 of about 3,353 (184)

Allergic Reactions and Cross-Reactivity Potential with Beta-Lactamase Inhibitors

Pharmacy, 2019
Although beta-lactam allergies are an emerging focus of stewardship programs and interventions, less is publicly released regarding allergies to beta-lactamase inhibitors. This review presents and evaluates the data regarding allergic reactions with beta-
Kayla R. Stover, Katie E. Barber, Jamie L. Wagner   +2 more
doaj   +1 more source

Pharmacodynamics of Doripenem Alone and in Combination with Relebactam in an In Vitro Hollow-Fiber Dynamic Model: Emergence of Resistance of Carbapenemase-Producing Klebsiella pneumoniae and the Inoculum Effect

Antibiotics, 2023
The emergence of bacteria resistant to beta-lactam/beta-lactamase inhibitor combinations is insufficiently studied, wherein the role of the inoculum effect (IE) in decreased efficacy is unclear.
Elena N. Strukova, Maria V. Golikova, Svetlana A. Dovzhenko, Mikhail B. Kobrin, Stephen H. Zinner   +4 more
doaj   +1 more source

Y-site Administration of Imipenem/Cilastatin/Relebactam With Common Intravenous Medications [PDF]

Clinical Therapeutics, 2020
Imipenem/cilastatin/relebactam has shown efficacy in complicated intra-abdominal and urinary tract infections in the RESTORE IMI-1 study, and it was recently approved by the US Food and Drug Administration. A press release announced that another Phase III study (RESTORE IMI-2) in patients with hospital-acquired and ventilator-associated pneumonia has ...
Islam M, Ghazi, Wasim S, El Nekidy, Ayush, Sood, Amanpreet, Dulku, Radha, Patel, Krishna, Patel, Pengfei, Li   +6 more
openaire   +2 more sources

Relebactam is a potent inhibitor of the kpc-2 -lactamase and restores imipenem susceptibility in kpc-producing enterobacteriaceae [PDF]

, 2018
The imipenem-relebactam combination is in development as a potential treatment regimen for infections caused by Enterobacteriaceae possessing complex -lactamase backgrounds. Relebactam is a -lactamase inhibitor that possesses the diazabicyclooctane core,
Alsop J., Papp-Wallace K.M., van Duin D., Kaye K.S., Bethel C.R., Bonomo R.A., Taracila M.A., Kreiswirth B.N., Barnes M.D., Becka S.A.   +9 more
core   +1 more source

Recent Developments to Cope the Antibacterial Resistance via β-Lactamase Inhibition

Molecules, 2022
Antibacterial resistance towards the β-lactam (BL) drugs is now ubiquitous, and there is a major global health concern associated with the emergence of new β-lactamases (BLAs) as the primary cause of resistance.
Zafar Iqbal, Jian Sun, Haikang Yang, Jingwen Ji, Lili He, Lijuan Zhai, Jinbo Ji, Pengjuan Zhou, Dong Tang, Yangxiu Mu, Lin Wang, Zhixiang Yang   +11 more
doaj   +1 more source

Rapid Detection of KPC-Producing Enterobacterales Susceptible to Imipenem/Relebactam by Using the MALDI-TOF MS MBT STAR-Carba IVD Assay

Frontiers in Microbiology, 2020
KPC-producing Enterobacterales represent a serious public health concern. Limited therapeutic options are available for treatment, however, the novel combination of imipenem/relebactam represents a promising alternative.
Marina Oviaño, Eva Gato, Germán Bou
doaj   +1 more source

Imipenem/relebactam érzékenységi vizsgálat E-teszttel karbapenem rezisztens Pseudomonas aeruginosa által okozott fertőzésekben

, 2022
A multirezisztens baktériumok (MRK) megjelenése és elterjedése, valamint az infekciók szempontjából magas kockázatú betegek számának emelkedése világszerte egyre nagyobb problémát okoz az egészségügyben. Az utóbbi években felbukkantak a karbapenemekre (
Ráti, Szabina
core  

In vitro studies evaluating the activity of imipenem in combination with relebactam against Pseudomonas aeruginosa

BMC Microbiology, 2019
Background The prevalence of antibiotic resistance is increasing, and multidrug-resistant Pseudomonas aeruginosa has been identified as a serious threat to human health. The production of β-lactamase is a key mechanism contributing to imipenem resistance
Katherine Young, Ronald E. Painter, Susan L. Raghoobar, Nichelle N. Hairston, Fred Racine, Douglas Wisniewski, Carl J. Balibar, Artjohn Villafania, Rumin Zhang, Daniel F. Sahm, Timothy Blizzard, Nicholas Murgolo, Milton L. Hammond, Mary R. Motyl   +13 more
doaj   +1 more source

Rapid detection of KPC-producing Enterobacterales by using a modified Carba NP test with imipenem/relebactam.

, 2022
20.500.12530/87858Here, we propose a novel modified Carba NP test for detecting KPC-producing Enterobacterales using imipenem/relebactam. The test performance was evaluated in a random selection of 160 previously molecularly characterized clinical ...
González-Bardanca, Mónica, Candela, Ana, Ramírez, Cecilia de la Luna, Oviaño, Marina, Bou, Germán   +4 more
core   +1 more source

A Clinical Review and Critical Evaluation of Imipenem-Relebactam: Evidence to Date.

Infection and drug resistance, 2020
Imipenem-relebactam (I-R) is a novel beta-lactam/beta-lactamase inhibitor combination given with cilastatin. It is indicated for the treatment of complicated urinary tract infections, complicated intra-abdominal infections, and hospital-acquired or ventilator-associated bacterial pneumonia.
Campanella,Toni A, Gallagher,Jason C
openaire   +5 more sources